Loading clinical trials...
Loading clinical trials...
Phase 3 placebo-controlled trial to determine efficacy of the probiotic LGG for reducing acute treatment related GI toxicity in patients with GI malignancy with phase 1 safety lead-in.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Washington University School of Medicine
NCT01750619 · Gastrointestinal Neoplasms, Benign Neoplasm of Intestinal Tract
NCT06663319 · Colorectal Neoplasms, Gastrointestinal Neoplasms
NCT06048146 · Lymph Node Metastasis, Cancer of Rectum and Anus, and more
NCT05551052 · Colorectal Cancer, Adenomas Colon, and more
NCT07389525 · Gastrointestinal Neoplasms, Genitourinary Cancer, and more
Washington University School of Medicine
St Louis, Missouri
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions